Prediction of cerebrovascular and cardiovascular events in patients with subclinical carotid atherosclerosis: The role of C-reactive protein

Journal of Investigative Medicine

Volumn 56, Issue 1, 2008, Pages 32-40

  Rizzo, Manfredi ^a   Corrado, Egle ^b   Coppola, Giuseppe ^b   Muratori, Ida ^b   Novo, Salvatore ^b  

^a Department of Clinical Medicine and Emerging Diseases ^*  (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atherosclerosis; C reactive protein; Events; Inflammation; Intimamedia thickness

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ACUTE HEART INFARCTION; ADULT; AGED; AGING; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS; DIABETES MELLITUS; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART DEATH; HELICOBACTER PYLORI; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBESITY; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; SMOKING CESSATION; STROKE; SUBCLINICAL CAROTID ATHEROSCLEROSIS; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; BLOOD; CAROTID ARTERY DISEASE; COMPARATIVE STUDY; DOPPLER FLOWMETRY; ECHOGRAPHY; METABOLISM; MIDDLE AGED; PROGNOSIS; TIME;

CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; HELICOBACTER PYLORI;

AGED; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER;

EID: 40949099022     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/jim.0b013e31816204ab     Document Type: Article

References (47)

1. Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation. 1990;82:1230-1242.
2. Wofford JL, Kahl FR, Howard GR, et al. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arteriosder Thromb. 1991;11:1786-1794.
3. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation. 1993;87:1156-1165.
4. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 1995;26:386-391.
5. Bots ML, Moons KG, Hollander M, et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Circulation. 1997;96: 1432-1437.
6. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. NEngl JMed. 1999; 340:14-22.
7. Corrado E, Rizzo M, Tantillo R, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke. 2006;37:482-486.
8. Corrado E, Novo S. Role of inflammation and infection in vascular disease. Acta ChirBelg. 2005;105:567-579.
9. Acevedo M, Foody JM, Pearce GL, et al. Fibrinogen: associations with cardiovascular events in an outpatient clinic. Am Heart J. 2002;143:277-282.
10. Folsom AR, Aleksic N, Catellier D, et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2002;144: 233-238.
11. Mazoyer E, Drouet L, Soria C, et al. Risk factors and outcomes for atherothrombotic disease in French patients: the RΓVAGE study. Risque VAsculaire Group d'Etude. Thromb Res. 1999;95:163-176.
12. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
13. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106: 3143-3421.
14. Pearson T, Mensah G, Alexander RW, et al. Markers of Inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice. A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
15. Mattila KJ, Valtonen W, Nieminen MS, et al. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clίn Infect Dis. 1998;26:719-734.
16. Espinola-Klein C, Rupprecht H, Blankenberg S, et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002;33:2581-2586.
17. Spence D, Norris J. Infection, inflammation, and atherosclerosis. Stroke. 2003;34:333-334.
18. Magyar MT, Szikszai Z, Balla J, et al. Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke. 2003;34:58-63.
19. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation. 2001;104: 63-67.
20. Sellmayer A, Limmert T, Hoffmann U. High sensitivity C-reactive protein in cardiovascular risk assessment. Int Angíol. 2003;22:15-23.
21. Murata M, Ide T. Determination of cholesterol in sub-nanomolar quantities in biological fluids by high-performance liquid chromatography. J Chromatogr. 1992;579:329-333.
22. Montagne P, Laroche P, Cuilliere ML, et al. Microparticle-enhanced nephelometric immunoassay for human C-reactive protein. J Clin Lab Anal. 1992;1:24-29.
23. Myers GL, Rifai N, Tracy R, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation. 2004;110:e545-549.
24. Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17: 231-237.
25. Imperatore G, Riccardi G, Iovine C, et al. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care. 1998;21:649-654.
26. Ridker PM, Kundsin RB, Stampfer MJ, et al. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation. 1999;99: 1161-1164.
27. Patel P, Mendall MA, Carrington D. Association of Helicobacter pylori and Chlamydia pneumoniae infection with coronary heart disease. BMJ. 1995;331:711-714.
28. Muhlestein JB. Chronic infection and coronary artery disease. Med Clin North Am. 2000;84:123-148.
29. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall. A direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1406.
30. 2003 European Society of Hypertension. Society of Cardiology Guidelines for the Management of Arterial Hypertension. JHypertens. 2003;21:1011-1053.
31. Pasceri V, Chang J, Willerson JT, et al. Direct proinflamma-tory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
32. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001 ;103: 1813-1818.
33. Greenland P, Smith SC, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people. Role of traditional risk factors and non invasive cardiovascular tests. Circulation. 2001;104:1863-1867.
34. Bard RL, Kalsi H, Rubenfire MD, et al. Effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention. Am J Cardiol. 2004;93: 1030-1032.
35. Coppola G, Corrado E, Muratori I, et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol. 2006;106:16-20.
36. Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation. 2006;113:38-43.
37. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. NEnglJMed. 2002; 347:1557-1565.
38. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N EnglJ Med. 2006;355:2631-2639.
39. Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007;116:32-38.
40. Michalsen A, Lehmann N, Pithan C, et al. Mediterranean diet has no effect on markers of inflammation and metabolic risk factors in patients with coronary artery disease. Eur J Clin Nutr. 2006;60:478-485.
41. García-Lorda P, Bulló M, Balanzà R, et al. C-reactive protein, adiposity and cardiovascular risk factors in a Mediterranean population. Int J Obes (Lond). 2006;30: 468-174.
42. Schillinger M, Exner M, Mlekusch W, et al. Inflammation and Carotid Artery-Risk for Atherosclerosis Study (ICARAS). Circulation. 2005;111:2203-2209.
43. Alvarez Garcia BA, Ruiz C, Chacon P, et al. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. JVascSurg. 2003;38:1018-1024.
44. Ridker P, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230-235.
45. Jialal D, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103: 1933-1935.
46. Albert MA, Danielson E, Rifai N, et al, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
47. Nissen SE, Tuzcu EM, Schoenhagen P, et al, Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.